CAS: 112809-52-6; 4,4'-((4H-1,2,4-Triazol-4-yl)Methylene)Dibenzonitrile

该化合物是一种化学化合物,其独特的结构包括三联星环和两个苯硝酸盐组,其特点是有机溶剂和潜在生物活动具有中度溶解性等特性,使其对包括药品和农用化学在内的各个领域具有兴趣.三联苯的出现表明,有可能作为杀真菌剂或药用化学应用,特别是在开发抗硫酸剂方面.此外,苯硝酸盐组可能助长其电子特性,影响其再活动性和与生物目标的相互作用.该化合物的稳定性和再活动可能受到环境条件的影响,例如pH和温度.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号288-88-0 1,2,4-三氮唑 | CAS号69545-39-7 4,4’-二氰基二苯溴甲烷 | CAS号112809-27-5 4-(4-氰基苄基)-1,2,4-三唑 | CAS号1194-02-1 对氟苯腈 | CAS号112809-25-3 4-(1H-1,2,4-三唑-...

合成工艺路线路线简述

    4-(4-氰基苄基)-1,2,4-噻唑,对氟苯腈置于potassium Tert-Butylate体系中,用 N,N-二甲基乙酰胺 用作溶剂,化学反应生成4,4'-(4H-1,2,4-三唑-4-基亚甲基)双苯腈
    参考文献:Cn116375657
    标题:Cn116375657

    海关参考信息

    专利信息


    专利号:WO-2010146391-A1
    优先权日:2009-06-15
    标题:Regioselective synthesis of letrozole
    发明人:GORE VINAYAK GOVIND; SHUKLA VINAY KUMAR; BHANDARI SHERYAS; HASBE SURESH; MEKDE SANDEEP
    权利人:GENERICS UK LTD; MYLAN INDIA PRIVATE LTD; GORE VINAYAK GOVIND; SHUKLA VINAY KUMAR; BHANDARI SHERYAS; HASBE SURESH; MEKDE SANDEEP
    摘要:The present invention relates to an improved process for the preparation of letrozole (I) and its pharmaceutically acceptable salts, to compositions comprising letrozole or a pharmaceutically acceptable salt thereof, and to uses of such compositions. In particular it relates to a process and to novel intermediates for preparing letrozole and its salts substantially free from regioisomeric impurities.

    专利号:US-7705159-B2
    优先权日:2005-07-06
    标题:Process for the preparation of letrozole
    发明人:MACDONALD PETER LINDSAY; BIGATTI ETTORE; ROSSETTO PIERLUIGI; HAREL ZVI
    权利人:SICOR INC
    摘要:The invention provides a high-yield process for the preparation of letrozole having a high purity, without the need for removal of the 4-[1-(1,3,4-triazolyl)methyl]benzonitrile impurity at the intermediate stage. The invention also provides a process for the synthesis of letrozole in which formation of the impurity 4-[1-(1,3,4-triazolyl)methyl]benzonitrile during the first stage is minimized. In the process, a 4-(halomethyl)benzonitrile is reacted with a salt of 1H-1,2,4-triazole, reducing the formation of the impurity. Preferably, the preparation is conducted as a one-pot process.

    专利号:US-8003804-B2
    优先权日:2006-03-17
    标题:Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate
    发明人:PATHI SRINIVAS LAXMINARAYAN; KANKAN RAJENDRA NARAYANRAO; RAO DHARMARAJ RAMACHANDRA; VASANT CHIKHALIKAR SANDIP
    权利人:CIPLA LTD
    摘要:The present invention relates to a process for the preparation of 4-[1-(4-cyano phenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile (letrozole), substantially free from its isomeric impurity. The preparation involves reaction of 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile with 4-fluorobenzonitrile in the presence of an organic solvent and a silicon amine. The present invention also relates to a process for the preparation of 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile which involves: (a) the reaction of a 4-halomethyl benzonitrile with 1,2,4-triazole in the presence of cesium carbonate and an organic solvent to obtain a reaction mass comprising 4-[1-(1,2,4-triazole-1-yl)methyl]benzonitrile of formula II; and (b) precipitation of 4-[1-(1,2,4-triazole-1-yl)methyl]benzonitrile (II) from the reaction mass using a suitable organic solvent.

    专利号:WO-2007107733-A1
    优先权日:2006-03-17
    标 题 :Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-tr1azol-1-yl)methyl] benzonitrile and 4-[1-(1h-1,2,4-triazol-1-yl)methylene benzonitrile intermediate

    专利号:US-2009270633-A1
    优先权日:2006-03-17
    标题 :Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate
    杭州灿瑞医药化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.canruipharm.com
    企业联系电话:0571-86728326👤
    📞杭州灿瑞医药化工有限公司 ⚠️参考联系方式
    联系人:杨先生
    电话:0571-86728326
    手机:15397015103
    传真:0571-86728326
    邮箱:sales@canruipharm.com
    通信地址: 杭州市拱墅区祥运路8号
    邮编: 310000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州市拱墅区祥运路8号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    药源药物化学(上海)有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.2ychem.com
    电话: 021-51320090👤
    📞药源药物化学(上海)有限公司 ⚠️参考联系方式

    销售电话:021-51320090
    邮箱:sales@2ychem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Roque M, Tostes AC, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecol Endocrinol. 2015;31(12):917-21. doi: 10.3109/09513590.2015.1096337. Epub 2015 Oct 19. Review. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. doi: 10.1111/jog.12393. Review. doi: 10.2147/DDDT.S83259. eCollection 2015.
    6: Li SJ, Zhang YJ, Chai XS, Nie MF, Zhou YY, Chen JL, Tao GS. Letrozole ovulation induction: an effective option in endometrial preparation for frozen-thawed embryo transfer. Arch Gynecol Obstet. 2014 Mar;289(3):687-93. Epub 2013 Oct 10. doi: 10.1158/1535-7163.MCT-14-0743. Epub 2015 Feb 18.
    8: Ketkaew C, Kiatying-Angsulee N. Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand. Asian Pac J Cancer Prev. 2015;16(14):6055-9. doi: 10.1158/1535-7163.MCT-15-0169. Epub 2015 Aug 26. doi: 10.1159/000367847. Epub 2014 Nov 22. doi: 10.1016/j.neuint.2015.10.001. Epub 2015 Oct 9. doi: 10.1371/journal.pone.0108219. eCollection 2014.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知